Synopsis of recent research by authors named "Teresa S Chai"
- Teresa S Chai's recent research highlights the implications of expanded mismatch repair (MMR) testing for cancer, including its potential to enhance eligibility for pembrolizumab treatment and facilitate Lynch syndrome screening across various tumor types.
- The investigation into real-world genetic testing outcomes for pan-cancer testing emphasizes the transition of MMR immunohistochemistry (IHC) testing from solely screening for Lynch syndrome to a broader application for mismatch repair-deficient tumors following FDA approval in 2017.
- Chai's study on mainstreamed genetic testing in breast cancer patients demonstrates the benefits of integrating genetic testing into surgical practice, showing improved timing and uptake of testing by allowing genetic assessments to occur in a single patient encounter, rather than through traditional referrals.
